Literature DB >> 16265484

The Fontan circulation: a challenge to William Harvey?

Marc R de Leval1.   

Abstract

The Fontan operation, which places the systemic and pulmonary circulations in series and is driven by a single ventricular chamber, is the treatment of choice for patients born with one ventricle. Its introduction 35 years ago was the result of a flurry of experimental and clinical research that had started in the 1940s. A large number of children have benefited and continue to benefit from the Fontan operation, but there is a genuine concern that, despite the refinement of the surgical procedures in the past 20 years, continuing attrition might be inevitable. This adverse effect can lead to a decline in functional capacity, and premature late death.

Entities:  

Mesh:

Year:  2005        PMID: 16265484     DOI: 10.1038/ncpcardio0157

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  24 in total

Review 1.  Cardiac resynchronization therapy for patients with congenital heart disease: technical challenges.

Authors:  Meera Manchanda; Christopher J McLeod; Ammar Killu; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2012-10-19       Impact factor: 1.900

Review 2.  Cavopulmonary assist: (em)powering the univentricular fontan circulation.

Authors:  Mark D Rodefeld; Steven H Frankel; Guruprasad A Giridharan
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2011

Review 3.  Four decades of Fontan palliation.

Authors:  Marc R de Leval; John E Deanfield
Journal:  Nat Rev Cardiol       Date:  2010-06-29       Impact factor: 32.419

Review 4.  Anesthetic management of noncardiac surgery for patients with single ventricle physiology.

Authors:  Koichi Yuki; Alfonso Casta; Shoichi Uezono
Journal:  J Anesth       Date:  2011-01-01       Impact factor: 2.078

Review 5.  Hypoplastic left heart syndrome: current considerations and expectations.

Authors:  Jeffrey A Feinstein; D Woodrow Benson; Anne M Dubin; Meryl S Cohen; Dawn M Maxey; William T Mahle; Elfriede Pahl; Juan Villafañe; Ami B Bhatt; Lynn F Peng; Beth Ann Johnson; Alison L Marsden; Curt J Daniels; Nancy A Rudd; Christopher A Caldarone; Kathleen A Mussatto; David L Morales; D Dunbar Ivy; J William Gaynor; James S Tweddell; Barbara J Deal; Anke K Furck; Geoffrey L Rosenthal; Richard G Ohye; Nancy S Ghanayem; John P Cheatham; Wayne Tworetzky; Gerard R Martin
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

6.  Preoperative B-type natriuretic peptide levels are associated with outcome after total cavopulmonary connection (Fontan).

Authors:  Monique Radman; Roberta L Keller; Peter Oishi; Sanjeev A Datar; Kari Wellnitz; Anthony Azakie; Frank Hanley; Danton Char; Jong-Hau Hsu; Rambod Amrinovin; Ian Adatia; Jeffrey R Fineman
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-27       Impact factor: 5.209

Review 7.  The Miracle Baby Grows Up: Hypoplastic Left Heart Syndrome in the Adult.

Authors:  Matthew Lewis; Marlon Rosenbaum
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

8.  Respiration Dependency of Caval Blood Flow in Patients with Fontan Circulation: Quantification Using 5D Flow MRI.

Authors:  Rene Bastkowski; Robert Bindermann; Konrad Brockmeier; Kilian Weiss; David Maintz; Daniel Giese
Journal:  Radiol Cardiothorac Imaging       Date:  2019-10-31

9.  Hemodynamic performance of stage-2 univentricular reconstruction: Glenn vs. hemi-Fontan templates.

Authors:  Kerem Pekkan; Lakshimi P Dasi; Diane de Zélicourt; Kartik S Sundareswaran; Mark A Fogel; Kirk R Kanter; Ajit P Yoganathan
Journal:  Ann Biomed Eng       Date:  2008-11-06       Impact factor: 3.934

10.  Sildenafil and ventriculo-arterial coupling in Fontan-palliated patients: a noninvasive echocardiographic assessment.

Authors:  Reza Shabanian; Leila Shahbaznejad; Anahita Razaghian; Abdolrazagh Kiani; Mitra Rahimzadeh; Soroush Seifirad; Armen Kocharian; Jami Shakibi Gilani; Mohammad Ali Navabi
Journal:  Pediatr Cardiol       Date:  2012-08-05       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.